Approximately 300,000 children under the age of 14 suffer from epilepsy. As a parent, if my child were susceptible to having seizures I would want to do anything I could to help prevent or limit those episodes as much as possible. There is much anecdotal evidence at this point that supports the positive effects of CBD and medical cannabis, such as  parents sharing stories on social media. But some real research needs to be done so that healthcare providers, parents and children are not only educated, but protected when utilizing this form of medication. 1

epilepsy and cannabisDoing research on medical cannabis for pediatric epilepsy can be extremely valuable to the children as well as the parents because many states prohibit the use of cannabis products by minors. This makes it extremely difficult for parents to gain access to this medication to help their children, thus putting them at risk of breaking the law or in some instances forcing families to uproot and move to other States in order to legally administer this life changing medication to their children.

While this is true of many forms of cannabis, recently the FDA  approved EPIDIOLEX® (cannabidiol, CBD) oral solution for the treatment of seizures associated with two epilepsy syndromes – Lennox-Gastaut syndrome and Dravet syndrome – in children two years of age or older. Epidiolex represents a new medication option for children with these types of epilepsy. It is also the first ever FDA approved medication to treat seizures in Dravet syndrome.(1)

In recent years there has been a public perception that cannabis is a potent, natural and safe alternative therapy for epilepsy. This has driven the demand for and use of cannabis and its derived products to treat epilepsy, especially in those patients whose seizures are medically intractable. Coupled with the media exposure showing examples of the apparent miraculous effects of CBD oil in select epileptic patients, treating physicians have struggled to balance the patient demand for cannabis products and the need for studies to determine their, efficacy, dosing, side-effect profile, and indications.(2)

This reinforces the need for further clinical study, which again as a parent I am extremely passionate about. No parent wants to see their child suffer when there are safe and effective treatments available.

Let’s further this mission and help the hundreds of thousands of children suffering from this awful disease.

Our mission at CannaTrials is to prove the benefit of specific cannabis products using clinical research, starting with our recent study, the PROMMISE Study. Please get involved, take the survey and share your experience with us!  We ask about your health condition, what kind of cannabis you are using, and what kind of relief you are getting.  With these results, we will educate the public and health professionals on how the public is using cannabis and getting relief, so that health professionals and patients can be better educated about the benefits of the cannabis plant.


About Julie Knytych

Julie Knytych is a seasoned business development expert with significant background in the healthcare and medical sectors. She is bringing new business collaborations to CannaTrials to build this business nationwide.